BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 11766333)

  • 1. [Experimental systems in CML biology].
    Maru Y
    Nihon Rinsho; 2001 Dec; 59(12):2322-8. PubMed ID: 11766333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
    Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson BS; Kohli V; Kantarjian H
    Cancer Res; 1993 Aug; 53(15):3603-10. PubMed ID: 8339266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential growth patterns in SCID mice of patient-derived chronic myelogenous leukemias.
    McGuirk J; Yan Y; Childs B; Fernandez J; Barnett L; Jagiello C; Collins N; O'Reilly RJ
    Bone Marrow Transplant; 1998 Aug; 22(4):367-74. PubMed ID: 9722072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blast crisis in a murine model of chronic myelogenous leukemia.
    Daley GQ; Van Etten RA; Baltimore D
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11335-8. PubMed ID: 1763047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
    Wertheim JA; Miller JP; Xu L; He Y; Pear WS
    Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytogenetic and clinical features of Philadelphia chromosome positive leukemias].
    Becher R; Kloke O
    Verh Dtsch Ges Pathol; 1990; 74():36-42. PubMed ID: 1708614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
    Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
    Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences between normal and CML stem cells: potential targets for clinical exploitation.
    Eaves AC; Barnett MJ; Ponchio L; Cashman JD; Petzer AL; Eaves CJ
    Stem Cells; 1998; 16 Suppl 1():77-83; discussion 89. PubMed ID: 11012149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
    Ren R
    Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of Ph' positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice.
    Skórski T; Nieborowska-Skórska M; Calabretta B
    Folia Histochem Cytobiol; 1992; 30(3):91-6. PubMed ID: 1286728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propagation of human blastic myeloid leukemias in the SCID mouse.
    Sawyers CL; Gishizky ML; Quan S; Golde DW; Witte ON
    Blood; 1992 Apr; 79(8):2089-98. PubMed ID: 1562735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
    Kuwabara T; Tanabe T; Warashina M; Xiong KX; Tani K; Taira K; Asano S
    Biomacromolecules; 2001; 2(4):1220-8. PubMed ID: 11777396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.